Quarterly ResultAug 10, 2026, 04:24 PM
Perspective Therapeutics Advances VMT-α-NET to Phase 3; Q2 Net Loss $26.8M
AI Summary
Perspective Therapeutics, Inc. reported a business update and Q2 2026 financial results, highlighting significant clinical progress and a strong financial position. The company is advancing its VMT-α-NET program toward a Phase 3 study in neuroendocrine tumors, with site activation targeted around year-end 2026. As of June 30, 2026, the company held approximately $237 million in cash, cash equivalents, and short-term investments, providing a cash runway into late 2027. For the second quarter, the net loss was $26.8 million, or $0.22 per share, as R&D expenses increased to $21.5 million.
Key Highlights
- VMT-α-NET program advancing toward Phase 3 study, site activation targeted year-end 2026.
- Cash, cash equivalents, and short-term investments totaled $237 million as of June 30, 2026.
- Cash runway expected to fund operations and milestones into late 2027.
- Net loss for Q2 2026 was $26.8 million, or $0.22 per basic and diluted share.
- Research and development expenses increased to $21.5 million in Q2 2026.
- VMT01 melanoma and PSV359 FAP-α clinical programs continue to advance.
- Chicago manufacturing facility expected to complete construction in early 2027.
- Paul Lyne, Ph.D. appointed Chief Science Officer in July 2026.
Price Impact
More from CATX